Huntington's Disease Research

Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.

Huntington's Disease Research Products Targets

Products for Huntington's Disease Research - Page 10

Cat.No. Product Name Information/Activity
BCC1234 Calpain Inhibitor II, ALLM Cathepsin inhibitor,Odanacatib (MK 0822) is a potent, selective, and neutral inhibitor of cathepsin K (human/rabbit) with IC50 of 0.2 nM/1 nM, and demonstrated high selectivity versus off-target cathepsin B, L, S. Phase 3.
BCC5139 Balicatib Balicatib(AAE-581) is a potent and selective inhibitor of cathepsin K; 10-100 fold more potent in cell-based enzyme occupancy assays than against cathepsin B, L, and S.
BCC1141 CA 074 CA-074 is a potent inhibitor of cathepsin B with a Ki of 2 to 5 nM.
BCC2361 L 006235 Potent cathepsin K inhibitor
BCC2362 SID 26681509 SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G.
BCC7104 A 68930 hydrochloride Potent, selective D<sub>1</sub>-like agonist
BCC7159 A 77636 hydrochloride Potent, selective D<sub>1</sub>-like agonist. Orally active
BCC7250 (R)-(-)-Apomorphine hydrochloride 314-19-2
BCC6991 CY 208-243 CY 208-243 is a selective dopamine D1 receptor agonist which exhibits antiparkinsonian activity.
BCC5681 Dihydrexidine hydrochloride (+)-Dihydrexidine hydrochloride ((+)-DAR-0100 hydrochloride) is a dopamine D1 receptor agonist with an EC50 of 72± 21 nM.